article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Since buying the chain, Amazon has made strategic expansions of its brick-and-mortar locations ( Connecticut , San Francisco , and Milwaukee ), increased IDN partnerships for specialty referrals to 18, and introduced healthcare-focused subscription services, including One Medical and RxPass.

Retail 52
article thumbnail

Healthcare Marketing Trends in 2024: How to StayAhead

Healthcare Success

Now that the holidays have drawn to a close, it’s time to return to your 2024 marketing plan and make adjustments that ensure your business is taking advantage of the latest trends in healthcare marketing to reach patients and HCPs more effectively and make a lasting impression.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five Good Reasons GoodRx Should Be in Your 2024 HCP Media Plan

PM360

Let’s get to the point: It’s time for pharma marketers and their media agencies to look beyond the “usual suspects” for new ways and new media partners to reliably deliver educational and promotional messages to healthcare providers (HCPs) specifically when they are in an action mindset.

Media 52
article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

Healthcare has a substantial carbon footprint, approximately 4% of global emissions and, of that, medicines generate up to one third. So far, only eight of the top 100 pharmaceutical companies by global prescription medicines sales have made a net zero commitment in the same date range.

article thumbnail

How to Thrive in the Wild West of New Targeting Techniques and Regulations

PM360

We can expect individual states to continue advancing their own privacy legislation, and cookies are officially disappearing after June 30, 2024, to boot. And what are the best tools and techniques to optically target patients and healthcare providers without running afoul of new regulations?

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

Ex-Novartis sales representative Steven Camburn filed a whistleblower case that claimed Novartis had paid doctors up to $3,500 to participate in educational speaker programs to increase the promotion and prescription of Gilenya. However, Novartis did not get the same reception while facing similar allegations in Greece.